The US Food and Drug Administration (FDA) has approved Lannett’s abbreviated new drug application (ANDA) of Loxapine Capsules in 5mg, 10mg, 25mg and 50mg doses.
Loxapine Capsules are therapeutically equivalent to Watson Pharmaceuticals’ Loxitane Capsules.
The company expects to start commercialising the product in the next few weeks.
Lannett president and CEO Arthur Bedrosian said they have now received five product approvals from the FDA over the last three months.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData